• Chronic Stress, Mitochondria, and Depression-Like Behavior

  2026-08-12

  A February 2025 study used chronic unpredictable mild stress (CUMS) in rats to connect depression-like behavior with mitochondrial dysfunction and inflammatory signaling in the hippocampus and prefrontal cortex. Its key advance was a mitochondrial-targeted antioxidant intervention: intracerebroventricular MnTBAP reduced stress-associated behavioral abnormalities, supporting mitochondrial dysfunction as a modifiable contributor rather than merely a correlated feature.

• Selective Nanomolar IRAP Inhibitors from Bestatin

  2026-08-12

  The reference study develops a stereoselective route to α-hydroxy-β-amino acid derivatives of bestatin and identifies a cell-active, low-nanomolar inhibitor of insulin-regulated aminopeptidase (IRAP) with more than 120-fold selectivity over related enzymes. Biochemical testing and X-ray crystallography show that interactions with the IRAP GAMEN loop are an important, previously underappreciated determinant of potency and selectivity.

• Letrozole Workflows for Breast Cancer Research

  2026-08-11

  Build reproducible aromatase-inhibition assays with Letrozole, from DMSO stock preparation through estrogen, ERα, and proliferation readouts. The workflow also shows how to distinguish estrogen-biosynthesis blockade from receptor-directed endocrine effects and how to troubleshoot model-specific variability.

• GDC-0994: Reading ERK1/2 Inhibition in Context

  2026-08-11

  GDC-0994 is a selective ERK1/2 inhibitor for studying pathway-dependent signaling in cancer and cholestatic injury models. This article explains how to interpret target engagement, connect zebrafish liver findings with oncology assays, and avoid common experimental overinterpretations.

• EdU Imaging Kits (HF594) for Treg Proliferation

  2026-08-10

  EdU Imaging Kits (HF594) provide antibody-free measurement of S-phase DNA synthesis for microscopy and flow cytometry, making them useful for resolving proliferation during Treg differentiation and drug-response studies. The workflow combines 5-ethynyl-2’-deoxyuridine labeling with HyperFluor™ 594 click chemistry while avoiding the harsh DNA denaturation required by BrdU assays.

• Liproxstatin-1 Workflows for Ferroptosis Research

  2026-08-09

  Liproxstatin-1 provides a practical rescue-control strategy for separating ferroptotic lipid damage from apoptosis or nonspecific oxidative stress. This guide connects cell-based validation, GPX4-deficient protection, renal injury models, and a carefully bounded extension to Candida albicans research.

• Mianserin HCl: From Trial Design to Assay Logic

  2026-08-08

  Mianserin HCl is more than a 5-HT2 receptor antagonist: its placebo-controlled clinical evidence provides a framework for separating receptor effects, sedation, exposure, and assay endpoints. This article translates that logic into rigorous antidepressant, receptor-signaling, cyclodextrin, and antipathogenic research workflows.

• RAB31 and ESCRT-Independent Exosome Biogenesis

  2026-08-07

  The reference study identifies active RAB31 as both a marker and regulator of an ESCRT-independent exosome pathway. It links EGFR-dependent RAB31 activation to flotillin-mediated intraluminal vesicle formation and TBC1D2B–RAB7 control of multivesicular endosome stability, providing a mechanistic framework for studying selective exosome cargo sorting.

• YM-155 Hydrochloride: Precision Targeting of Survivin in Can

  2026-08-07

  Explore how YM-155 hydrochloride, a potent survivin inhibitor, enables advanced mechanistic studies in cancer research. This article uniquely analyzes assay interpretation and translational potential, providing actionable insights beyond standard protocol workflows.

• Erastin: Mechanistic Leverage Points for Translational Ferro

  2026-08-06

  This thought-leadership article explores Erastin’s role as a ferroptosis inducer, elucidating its mechanistic underpinnings, workflow strategies, and translational potential for cancer and oxidative stress research. Drawing on the latest evidence—including insights into the NF-κB/PTGS2 axis in melanocyte ferroptosis—this piece offers strategic guidance for researchers seeking reproducible, impactful results. It differentiates itself from conventional product pages by integrating advanced experimental recommendations, cross-domain relevance, and a visionary outlook for clinical translation.

• Lopinavir Identified as Potent Inhibitor of MERS-CoV Replica

  2026-08-06

  de Wilde et al. systematically screened 348 FDA-approved compounds, identifying lopinavir among four small molecules that robustly inhibit MERS-CoV replication in vitro. This work provides a rapid, evidence-based path for repurposing existing antivirals and informs future research on cross-pathogen therapeutic strategies.

• Deferasirox: Precision Iron Chelation and Tumor Ferroptosis

  2026-08-05

  Explore how Deferasirox, a leading oral iron chelator, enables advanced control of iron metabolism and ferroptosis in cancer research. This in-depth article uniquely connects molecular mechanisms to practical protocol design and emerging strategies for overcoming tumor resistance.

• Ferulic Acid Mitigates Chemotherapy-Induced POI via ER Stres

  2026-08-05

  This study demonstrates that ferulic acid (FA) alleviates chemotherapy-induced premature ovarian insufficiency (POI) by targeting endoplasmic reticulum (ER) stress, specifically through inhibition of the Grp78 and Perk/eIF2α/ATF4/CHOP pathways. The findings provide mechanistic insight into FA’s protective effects on granulosa cells and suggest new directions for ovarian and apoptosis research.

• Cy5.5 NHS Ester (Non-Sulfonated): Precision Labeling for Neu

  2026-08-04

  Discover how Cy5.5 NHS ester (non-sulfonated) enables advanced, high-sensitivity labeling for in vivo neuromodulation studies and molecular imaging. Explore its unique chemical properties, workflow optimizations, and novel applications that set it apart from conventional near-infrared dyes.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer to P

  2026-08-04

  Mei et al. (2025) demonstrate that hyperthermia-mediated reduction of BRCA2 protein levels significantly enhances the sensitivity of BRCA2-proficient ovarian carcinoma cells to PARP inhibition, specifically Niraparib. This combination strategy addresses a major mechanism of drug resistance and offers new directions for DNA damage repair inhibition research.

11413 records 1/761 page Next 12345 下5页 Last page